Sucampo Pharma (SCMP) Cash Flow Statement

Click line-items for a historical chart and %

Net income (loss)	3.2M
Depreciation and amortization	37.87M
Loss on disposal of fixed assets	535K
Deferred tax provision
Stock-based compensation	5.45M
Amortization of premiums on investments	0
Notes payable paid-in-kind interest
Interest expense
Realized gain on trading securities
Realized loss on settlement rights of auction rate securities
Accounts receivable	3.53M
Unbilled accounts receivable
Product royalties receivable	2.02M
Prepaid and income taxes receivable and payable, net
Accounts payable	-4.09M
Accrued expenses	-2.41M
Deferred revenue	-38K
Other assets and liabilities, net	755K
Net cash used in operating activities	30.29M
Purchases of investments	-250K
Proceeds from sales of investments
Maturities of investments	0
Purchases of property and equipment	-1.22M
Proceeds from disposals of property and equipment
Purchases of intangible assets
Net cash provided by investing activities	-1.84M
Issuance of notes receivable
Proceeds from exercise of stock options	1.66M
Proceeds from employee stock purchase plan	174K
Net cash provided by (used in) financing activities	-16.36M
Effect of exchange rates on cash and cash equivalents	8.09M
Net increase in cash and cash equivalents	20.18M
Cash and cash equivalents at beginning of period	108.28M
Cash and cash equivalents at end of period	128.47M
Purchase of intangible assets included in accrued expenses

Entities mentioned with SCMP

View All Entities